- Home
- ATNM vs NRT Comparison
ATNM vs NRT Comparison
Compare ATNM & NRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- NRT
- Stock Information
- Founded
- ATNM 2000
- NRT 1975
- Country
- ATNM United States
- NRT United States
- Employees
- ATNM N/A
- NRT N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- NRT Oil & Gas Production
- Sector
- ATNM Health Care
- NRT Energy
- Exchange
- ATNM Nasdaq
- NRT Nasdaq
- Market Cap
- ATNM 50.2M
- NRT 46.4M
- IPO Year
- ATNM N/A
- NRT N/A
- Fundamental
- Price
- ATNM $1.61
- NRT $5.21
- Analyst Decision
- ATNM Strong Buy
- NRT
- Analyst Count
- ATNM 2
- NRT 0
- Target Price
- ATNM $4.50
- NRT N/A
- AVG Volume (30 Days)
- ATNM 122.2K
- NRT 41.6K
- Earning Date
- ATNM 11-13-2025
- NRT 08-29-2025
- Dividend Yield
- ATNM N/A
- NRT 9.24%
- EPS Growth
- ATNM N/A
- NRT 24.05
- EPS
- ATNM N/A
- NRT 0.59
- Revenue
- ATNM N/A
- NRT $6,184,173.00
- Revenue This Year
- ATNM N/A
- NRT N/A
- Revenue Next Year
- ATNM N/A
- NRT N/A
- P/E Ratio
- ATNM N/A
- NRT $8.98
- Revenue Growth
- ATNM N/A
- NRT 18.55
- 52 Week Low
- ATNM $1.03
- NRT $3.88
- 52 Week High
- ATNM $2.41
- NRT $5.75
- Technical
- Relative Strength Index (RSI)
- ATNM 45.72
- NRT 49.67
- Support Level
- ATNM $1.60
- NRT $4.90
- Resistance Level
- ATNM $1.70
- NRT $5.39
- Average True Range (ATR)
- ATNM 0.07
- NRT 0.16
- MACD
- ATNM -0.01
- NRT 0.01
- Stochastic Oscillator
- ATNM 32.14
- NRT 63.27
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.